Published in Qual Life Res on January 01, 2000
Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes (2007) 3.43
How young can children reliably and validly self-report their health-related quality of life?: an analysis of 8,591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes (2007) 3.23
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Patient expectations and patient-reported outcomes in surgery: a systematic review. Surgery (2013) 1.76
A Wireless Health Outcomes Monitoring System (WHOMS): development and field testing with cancer patients using mobile phones. BMC Med Inform Decis Mak (2004) 1.72
Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients. J Pediatr (2009) 1.47
The PedsQL as a patient-reported outcome in children and adolescents with Attention-Deficit/Hyperactivity Disorder: a population-based study. Health Qual Life Outcomes (2006) 1.40
The PedsQL as a patient-reported outcome in children and adolescents with fibromyalgia: an analysis of OMERACT domains. Health Qual Life Outcomes (2007) 1.38
Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care (2005) 1.33
Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer (2013) 1.31
The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord (2009) 1.17
Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract (2013) 1.15
The pediatric quality of life inventory (PedsQL) family impact module: reliability and validity of the Brazilian version. Health Qual Life Outcomes (2008) 1.13
Measurement properties of the Brazilian version of the Pediatric Quality of Life Inventory (PedsQL) cancer module scale. Health Qual Life Outcomes (2008) 1.11
The reliability and validity of the SF-8 with a conflict-affected population in northern Uganda. Health Qual Life Outcomes (2008) 1.11
Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes (2005) 1.11
Health status in routine clinical practice: validity of the clinical COPD questionnaire at the individual patient level. Health Qual Life Outcomes (2010) 1.10
The PedsQL Present Functioning Visual Analogue Scales: preliminary reliability and validity. Health Qual Life Outcomes (2006) 1.06
Psychometric properties of the Brazilian version of the Early Childhood Oral Health Impact Scale (B-ECOHIS). BMC Oral Health (2011) 1.05
PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr (2013) 1.02
PedsQL™ sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer (2013) 1.00
Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale. Qual Life Res (2011) 0.99
Do nurses provide holistic care to cancer patients? Iran J Nurs Midwifery Res (2010) 0.94
Dyadic concordance among prostate cancer patients and their partners and health-related quality of life: does it matter? Psychol Health (2011) 0.93
Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes (2009) 0.91
Quality of life, anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer (2009) 0.90
End of life care in chronic obstructive pulmonary disease: in search of a good death. Int J Chron Obstruct Pulmon Dis (2008) 0.90
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 0.90
Measuring health-related quality of life in children with cancer living in Mainland China: feasibility, reliability and validity of the Chinese Mandarin version of PedsQL 4.0 Generic Core Scales and 3.0 Cancer Module. Health Qual Life Outcomes (2011) 0.90
Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surg Endosc (2011) 0.88
The top 13: what family physicians should know about prostate cancer. Can Fam Physician (2008) 0.88
Health-related quality of life and cognitive functioning in pediatric short stature: comparison of growth-hormone-naïve, growth-hormone-treated, and healthy samples. Eur J Pediatr (2010) 0.86
[The benefits of using patient-reported outcomes in cancer treatment: an overview]. Wien Klin Wochenschr (2012) 0.85
PedsQL™ Cognitive Functioning Scale in pediatric liver transplant recipients: feasibility, reliability, and validity. Qual Life Res (2010) 0.85
Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes (2016) 0.85
Reliability and validity of the Chinese version of the Pediatric Quality Of Life InventoryTM (PedsQLTM) 3.0 neuromuscular module in children with Duchenne muscular dystrophy. Health Qual Life Outcomes (2013) 0.84
Health related quality of life in patients with biliary atresia surviving with their native liver. J Pediatr (2013) 0.83
Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. Neuromuscul Disord (2014) 0.81
Oncologists' assessments of lung cancer patient and family disagreements regarding treatment decision making. Lung Cancer (2012) 0.79
Health related quality of life of children with rheumatic heart diseases: reliability of the Brazilian version of the Pediatric Quality of Life Inventory™ Cardiac Module scale. Health Qual Life Outcomes (2013) 0.79
Development of the Chinese family support scale in a sample of Chinese patients with hypertension. PLoS One (2013) 0.79
Differences in physicians' and patients' perception of acute hypothyroid symptoms induced by thyroid hormone withdrawal in thyroid cancer patients: a multicenter survey in Korea. Eur Thyroid J (2015) 0.78
[Pain experience and pain therapy of tumor patients in the view of general practitioners]. Schmerz (2005) 0.76
Evaluation of dog owners' perceptions concerning radiation therapy. Acta Vet Scand (2009) 0.76
Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life. Front Oncol (2016) 0.75
Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians. JIMD Rep (2011) 0.75
Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome. J Pediatr (2015) 0.75
Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life. Gynecol Oncol (2016) 0.75
Systematic review of caregiver responses for patient health-related quality of life in adult cancer care. Qual Life Res (2017) 0.75
Comparing Patient, Casual Observer, and Expert Perception of Permanent Unilateral Facial Paralysis. JAMA Facial Plast Surg (2017) 0.75
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer (1968) 4.88
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res (1970) 2.47
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 2.34
Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ (1998) 2.24
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Quality of cancer care. Ann Oncol (2004) 2.01
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
The proliferation of capillary endothelial cells. Cancer Res (1972) 1.81
Bone metastases: pathophysiology and management policy. J Clin Oncol (1991) 1.70
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer (1980) 1.68
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol (1972) 1.67
How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol (1988) 1.65
Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol (2001) 1.57
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol (2002) 1.56
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication. Ann Oncol (1992) 1.54
Photorhabdus virulence cassettes confer injectable insecticidal activity against the wax moth. J Bacteriol (2006) 1.49
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer (2001) 1.47
Visual results in children treated for macular retinoblastoma. Eye (Lond) (2002) 1.45
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol (2007) 1.42
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol (2006) 1.39
Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst (1969) 1.39
Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys (2000) 1.37
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer (1980) 1.33
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Influence of vitamin A on immunological response. Immunology (1972) 1.28
Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol (2001) 1.28
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol (1997) 1.25
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res (1999) 1.24
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ (1998) 1.20
Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res (1986) 1.19
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
On the existence of a G 0 -phase in the cell cycle. Cell Tissue Kinet (1970) 1.17
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2014) 1.17
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol (1998) 1.12
Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res (1989) 1.10
Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer (2006) 1.10
The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer (1998) 1.09
Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. J Natl Cancer Inst (1972) 1.09
Information from the Internet: attitudes of Australian oncology patients. Intern Med J (2006) 1.08
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol (1994) 1.07
Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer (1993) 1.07
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol (2013) 1.06
Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res (1983) 1.05
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer (1996) 1.05
Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res (1992) 1.04
Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst (1990) 1.04
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.03
A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia (2003) 1.03
Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res (1998) 1.02
A comparison of cell proliferation parameters in solid and ascites Ehrlich tumors. Cancer Res (1969) 1.00
Upper limb work-related musculoskeletal disorders among newspaper employees: cross-sectional survey results. Am J Ind Med (1997) 0.99
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol (1986) 0.99
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer (1997) 0.98
Tumor growth and cell kinetics in chronically hypoxic animals. J Natl Cancer Inst (1970) 0.97
Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br J Cancer (1993) 0.96
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol (1985) 0.94
Systemic treatment for prostate cancer. Cancer Treat Rev (1998) 0.94
Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.94
Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res (1986) 0.94
Chemotherapy for adenocystic carcinoma. Cancer (1980) 0.93
How valid are claims for synergy in published clinical studies? Ann Oncol (2012) 0.93
Prostate cancer: 11. Alternative approaches and the future of treatment. CMAJ (1999) 0.93
Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br J Cancer (2002) 0.93
Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet (2000) 0.93
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer (2000) 0.93
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol (2009) 0.92
Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst (1989) 0.90
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol (2002) 0.90
The translational research chain: is it delivering the goods? Int J Radiat Oncol Biol Phys (2001) 0.90
Treating the patient, not just the cancer. N Engl J Med (1987) 0.89
Removing the primary tumor after the cancer has spread. N Engl J Med (2001) 0.89
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
Quality of life and understanding of disease status among cancer patients of different ethnic origin. Br J Cancer (2003) 0.88
Global drug development in cancer: a cross-sectional study of clinical trial registries. Ann Oncol (2009) 0.88
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol (2009) 0.88
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol (1998) 0.87
Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res (1993) 0.87
Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer (2001) 0.86
Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosis. Br J Cancer (1986) 0.86
Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin. Int J Cancer (1995) 0.86
The changing face of hormonal therapy for prostate cancer. Ann Oncol (2008) 0.85
Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. Cancer Res (1984) 0.85
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol (1999) 0.85
The potential of lactate and succinate to kill nutrient deprived tumor cells by intracellular acidification. Int J Radiat Oncol Biol Phys (1991) 0.84
Quality of life measurement in breast cancer patients. Br J Cancer (1985) 0.84
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. Br J Cancer (1994) 0.84
Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol (1998) 0.84
Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues? Br J Cancer (1990) 0.83
Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol (2004) 0.83
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol (1999) 0.82